Equity · Healthcare
COLL
NASDAQCollegium Pharmaceutical (COLL)
The line runs 26 USD on 12 August through 24.71 USD on 9 November, on a scale from 20.0 to 30.0. Days the market did not trade hold the previous close, flat.
- Market cap
- 767.9M USD
- P/E (TTM)
- 24.7
- Revenue, year to Dec 2025
- 780.6M USD
- EPS, diluted, year to Dec 2025
- 1.73 USD
- 52-week range
- 22 USD – 52.55 USD
- Avg volume
- 49.8K
- Mentions, 30 days
- 2
as of Nov 9, 2026
Have Collegium Pharmaceutical (COLL) insiders bought or sold shares recently?
COLL's newest Form 4 filing is dated 8 June 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 18 May 2026 | Freund John GordonDirector | Sell | 20 | 681 USD |
| 15 May 2026 | Freund John GordonDirector | Sell | 4,127 | 143K USD |
| 13 May 2026 | Lurker NancyDirector | Sell | 4,500 | 162K USD |
| 11 May 2026 | BOHLIN GAREN GDirector | Sell | 8,700 | 323K USD |
| 18 Mar 2026 | Dieter DavidEVP & General Counsel | Sell | 13,976 | 488K USD |
| 09 Mar 2026 | Dieter DavidEVP & General Counsel | Sell | 6,224 | 228K USD |
| 03 Mar 2026 | Dreyer ScottEVP & Chief Commercial Officer | Sell | 49,976 | 2.0M USD |
| 08 Dec 2025 | Dreyer ScottEVP & Chief Commercial Officer | Sell | 17,600 | 848K USD |
| 05 Dec 2025 | Balice-Gordon Rita J. | Sell | 3,650 | 172K USD |
| 12 Nov 2025 | Fallon John A. | Sell | 34,853 | 1.6M USD |
| 06 Nov 2025 | Tupper ColleenEVP & Chief Financial Officer | Sell | 30,000 | 1.2M USD |
| Sold | 11 open-market sales | 173,626 | $7.25M |
24 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 08 Jun 2026 | SANTINI GINODirector | Option exercise | 8,700 | 143K USD |
| 15 May 2026 | Freund John GordonDirector | Option exercise | 8,700 | 143K USD |
| 14 May 2026 | BOHLIN GAREN GDirector | Award | 8,741 | |
| 14 May 2026 | Balice-Gordon Rita J.Director | Award | 8,741 | |
| 14 May 2026 | SANTINI GINODirector | Award | 8,741 | |
| 14 May 2026 | Freund John GordonDirector | Award | 8,741 | |
| 14 May 2026 | Lurker NancyDirector | Award | 8,741 | |
| 14 May 2026 | Paya Carlos VDirector | Award | 8,741 | |
| 14 May 2026 | Glancy Donovan MichaelDirector | Award | 17,482 | |
| 11 May 2026 | BOHLIN GAREN GDirector | Option exercise | 8,700 | 143K USD |
| 17 Mar 2026 | Dieter DavidEVP & General Counsel | Tax withheld | 8,840 | 316K USD |
| 10 Feb 2026 | Karnani VikramPresident and CEO | Award | 111,795 |
Showing the 12 most recent of 24 compensation filings in this window. The figures above count all of them.
Which funds hold Collegium Pharmaceutical (COLL)?
8 of the 45 institutional funds we track reported a Collegium Pharmaceutical position for the quarter ended 30 Jun 2026 — a combined 113.5M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Held (±25%) | 1,366,549 | 49.5M USD | −7.0% |
| Millennium Management | Added | 736,925 | 26.7M USD | +104.2% |
| D. E. Shaw & Co. | Trimmed | 338,383 | 12.2M USD | −36.2% |
| Marshall Wace | Trimmed | 253,353 | 9.2M USD | −66.2% |
| AQR Capital Management | Held (±25%) | 149,802 | 5.4M USD | +10.8% |
| Point72 Asset Management | New position | 114,006 | 4.1M USD | |
| Two Sigma Investments | Trimmed | 106,704 | 3.9M USD | −81.9% |
| Citadel Advisors | Trimmed | 68,592 | 2.5M USD | −43.5% |
| Balyasny Asset Management | Exited | |||
| Man Group | Exited |
What has been filed or recorded for Collegium Pharmaceutical (COLL)?
The filings we hold for Collegium Pharmaceutical, newest first: 2 fails-to-deliver days, 4 quarterly earnings reports, 3 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 18 shares | 398 USD notional · <0.001% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 9,325 shares | 205K USD notional · 0.029% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.60 USD | Revenue $216M |
| 30 Sep 2026 | Financials | Total assets | 2.1B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 296.4M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.46 USD | Revenue $200M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.40 USD | Revenue $194M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 0.46 USD | Revenue $205M |
| 31 Dec 2025 | Financials | Revenue | 780.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 62.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 1.73 USD | fiscal year |
| 30 Sep 2025 | Annual report | FY 2025 reported | EPS 0.84 USD | Revenue $209M |
| 30 Jun 2025 | Annual report | FY 2025 reported | EPS 0.34 USD | Revenue $188M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.07 USD | Revenue $178M |
What is Reddit saying about Collegium Pharmaceutical (COLL)?
Reddit mentioned COLL 2 times in the 30 days to 10 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 0% read bullish, 0% bearish and 100% neither. Reddit data updated 10 November 2026.
30-day window, Method
How do Reddit mentions of Collegium Pharmaceutical (COLL) compare with its price?
Share ↗
Which subreddits are talking about Collegium Pharmaceutical (COLL)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 100% | 2 | +0.03 |
What do people ask about Collegium Pharmaceutical (COLL)?
What did Collegium Pharmaceutical shares close at?24.71
Collegium Pharmaceutical closed at 24.71 USD on 9 Nov 2026, up 2.11% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Collegium Pharmaceutical’s market cap?767.9M
Collegium Pharmaceutical is worth 767.9M USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Collegium Pharmaceutical’s P/E ratio?24.7
Collegium Pharmaceutical has a price-to-earnings ratio of 24.7, as of 9 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Collegium Pharmaceutical’s revenue?780.6M
Collegium Pharmaceutical reported revenue of 780.6M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Collegium Pharmaceutical insiders bought or sold shares recently?
No Collegium Pharmaceutical insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 8 Jun 2026 (SEC Form 4). See Insiders
Which funds own Collegium Pharmaceutical?8 of 45
8 of the 45 funds we track reported a Collegium Pharmaceutical position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Millennium Management and D. E. Shaw & Co. See Funds
When did Collegium Pharmaceutical last report earnings?0.60
Collegium Pharmaceutical last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.60 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Collegium Pharmaceutical?1 mentions
Collegium Pharmaceutical was mentioned 1 times in the last 7 days across the finance subreddits we track, and 2 times over the trailing 30 days. Of the 2 mentions scored for sentiment, 0% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings